NEW YORK, NY -- (MARKET WIRE) -- April 02, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the results of operations for the year ended December 31, 2006. The Company had a loss of $0.17 cents per share in 2006 vs. a loss of $0.29 cents in 2005. The loss from operations expanded to ($5,436,671) in 2006 from ($4,915,193) in 2005. The increased expenses are directly attributable to the expansion of the Company's research, development, and marketing efforts. Total costs and expenses for 2006 were up 11% from 2005. This was due to the planned increase in expenses as the Company continues to expand its research and development efforts associated with the Blood Volume Analyzer as well increases to the marketing staff.
